Literature DB >> 16723812

HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.

Kotaro Tokinaga1, Toru Oeda, Yoshifumi Suzuki, Yasuhisa Matsushima.   

Abstract

Serious side effects of statins, including severe myopathy and rhabdomyolysis, are rare but important in general practice. Hypothyroidism can cause secondary hypercholesterolemia and myopathy. There have been few reports on the risk of statins in patient with unnoticed hypothyroidism. We analyzed the characteristics of 77 patients with primary hypothyroidism in our hospital. Nine patients (11%) accidentally received statins in the treatment of hypercholesterolemia without diagnosis of hypothyroidism. In such patients, free T4 (FT4) levels were lower, and those of LDH, CK were higher than those in patients not receiving statins. In patients accidentally receiving statins, an inverse correlation between CK and FT4 could not be shown (which was recognized in patients not receiving them). Even after FT4 levels were matched, levels of CK were still higher in the patients accidentally receiving statins. Patients with high CK levels over 1000 U/L were 5 times more frequent (56%) in patients accidentally receiving statins than in those not receiving statins (11%). The present study confirms that statins enhances levels of CK in patients with hypothyroidism. We must not begin and continue to use these drugs without checking the possibility of hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723812     DOI: 10.1507/endocrj.k04-144

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  14 in total

1.  Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) Position Statement : Diabetes mellitus and thyroid disorders: recommendations for clinical practice.

Authors:  Edoardo Guastamacchia; Vincenzo Triggiani; Alberto Aglialoro; Antimo Aiello; Lucia Ianni; Mauro Maccario; Michele Zini; Carlo Giorda; Rinaldo Guglielmi; Corrado Betterle; Roberto Attanasio; Giorgio Borretta; Piernicola Garofalo; Enrico Papini; Roberto Castello; Antonio Ceriello
Journal:  Endocrine       Date:  2014-11-18       Impact factor: 3.633

2.  Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report.

Authors:  Yaser Jbara; Dean Bricker
Journal:  Eur Thyroid J       Date:  2015-02-18

3.  Severe rhabdomyolysis and acute renal failure secondary to the use of simvastatin in undiagnosed hypothyroidism.

Authors:  F A Qari
Journal:  Indian J Nephrol       Date:  2008-01

Review 4.  Statin myopathy.

Authors:  Kristofer A Radcliffe; William W Campbell
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

Review 5.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

6.  Effects of thyroid dysfunction on lipid profile.

Authors:  C V Rizos; M S Elisaf; E N Liberopoulos
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

7.  Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone.

Authors:  Shereen Elazzazy; Saad S Eziada; Manal Zaidan
Journal:  Int Med Case Rep J       Date:  2012-09-04

8.  Hypothyroidism complicating nephropathy in a diabetes patient.

Authors:  Jayaprakash Sahoo; Ilangovan Veerappan; Anila Abraham; Somasundaram Hariharan
Journal:  Case Rep Endocrinol       Date:  2012-12-10

9.  Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report.

Authors:  Ekrem Yeter; Telat Keles; Tahir Durmaz; Engin Bozkurt
Journal:  J Med Case Rep       Date:  2007-11-10

10.  Rhabdomyolysis-induced acute kidney injury in a patient with non-compliance to levothyroxine therapy.

Authors:  Ayesha Ghayur; Qurrat Elahi; Chinmay Patel; Rishi Raj
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.